These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 1520901

  • 1. A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.
    Scionti L, Misericordia P, Santucci A, Santeusanio F, Brunetti P.
    Acta Diabetol; 1992; 29(1):20-4. PubMed ID: 1520901
    [Abstract] [Full Text] [Related]

  • 2. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [Abstract] [Full Text] [Related]

  • 3. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S.
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [Abstract] [Full Text] [Related]

  • 4. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [Abstract] [Full Text] [Related]

  • 5. Effect of oral antidiabetic drug withdrawal in type 2 diabetes.
    Nobels F, Van Gaal L, Rillaerts E, De Leeuw I.
    Diabet Med; 1989 Mar; 6(2):149-51. PubMed ID: 2522858
    [Abstract] [Full Text] [Related]

  • 6. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 7. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
    Wolffenbuttel BH, Weber RF, Weeks L, van Koetsveld PM, Verschoor L.
    Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
    [Abstract] [Full Text] [Related]

  • 8. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents.
    Iavicoli M, Cucinotta D, De Mattia G, Lunetta M, Morsiani M, Pontiroli AE, Pozza G.
    Diabet Med; 1988 Dec; 5(9):849-55. PubMed ID: 2976646
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.
    Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy.
    Grant PJ, Barlow E, Miles DW.
    Diabet Med; 1984 Nov; 1(4):284-6. PubMed ID: 6242818
    [Abstract] [Full Text] [Related]

  • 13. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Metabolic effect of islet B-cell function in insulin-treated diabetes.
    Gjessing HJ, Matzen LE, Iversen S, Faber OK, Frøland A.
    Scand J Clin Lab Invest; 1989 Jun; 49(4):337-43. PubMed ID: 2662383
    [Abstract] [Full Text] [Related]

  • 18. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
    Iwasaki Y, Kondo K, Hasegawa H, Oiso Y.
    Diabetes Res; 1994 Jun; 25(3):129-37. PubMed ID: 7671552
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.